Bloomgarden 2024
Tuttavia, questo medicinale diventato protagonista di una vera e propria moda per la perdita di peso, con una conseguente aumento esponenziale di richieste
[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S
Reduction in Visceral Fat Unlike many weight loss interventions, GLP-1s specifically target visceral fat (fat around the organs), which is the most dangerous kind linked to insulin resistance, inflammation, and heart disease
Statistical Summary 17,604: Number of adults enrolled in the SELECT trial, all with cardiovascular disease and obesity but no diabetes 20%: Relative reduction in major cardiovascular events with semaglutide 2.4 mg compared to placebo 6.5% vs 8.0%: Actual event rates in the semaglutide group versus the placebo group over roughly 3.3 years 9.4%: Mean body weight lost by participants taking semaglutide during the trial 0.80: The hazard ratio, the single number that tells you how much lower your cardiovascular risk becomes on this drug 16.6%: Percentage of semaglutide patients who stopped the drug due to serious adverse events, compared to 8.2 percent on placebo Bottom Line The myth I need to bury today is this one: weight loss drugs are cosmetic
